Company intelligence / Profile preview
Wellstat Therapeutics Corporation
Gaithersburg, Maryland, USAorpha.net ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Commercial
01
Overview
Wellstat Therapeutics has achieved FDA approval for uridine triacetate under the brand names Vistogard and Xuriden. Vistogard is approved for emergency treatment of overdose from certain chemotherapies, while Xuriden treats hereditary orotic aciduria. The pipeline includes additional small molecule therapeutics targeting oncology and metabolic disorders at various clinical stages.
- Therapeutic areas
- OncologyMetabolic DisordersNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Wellstat Therapeutics Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wellstat Therapeutics Corporation.